Chapel Hill drug company Pozen reported this morning that it posted a $13.3 million profit in the second-quarter -- reversing its loss of a year ago -- thanks to a $20 million milestone payment from partner GlaxoSmithKline.
56787
Pozen posts profit
147065
Glaxosmithkline not to pursue further worldwide development of Simplirix
4679
Solid Energy returns to interim profit
108888
Pain Therapeutics receives $5,000,000 payment
18385
Akzo Nobel climbs as purge on costs helps profit beat estimates
124135
Gastric cancer drug market to double to nearly $1.5 billion in 2018
95570
SugarCRM raises $33 million
155748
Drug company stands to benefit from legislation
147662
Galenica's kidney drug meets endpoint in trial
7754
GlaxoSmithKline files for European approval of diabetes drug albiglutide
11092
Nash Finch swings to profit
70808
Merck presents positive data
132990
Burger King 1Q profit rises 2 percent
53579
Vertex Pharmaceuticals loss widens
22797
Salix Pharmaceuticals is building on recent gains during Thursday's trading
97434
Amicus Therapeutics initiates trial of AT2220 in Pompe disease
79889
Merck buys drug rival Schering-Plough